rel-tert-Butyl ((1R,2S)-2-fluorocyclopropyl)carbamate

Catalog No.: 
ACGRXL164
CAS No.: 
105919-35-5
Molecular Formula: 
C8H14FNO2
Molecular Weight: 
175.20
rel-tert-Butyl ((1R,2S)-2-fluorocyclopropyl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$150.00InquiryInquiry
1g95%$337.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Namerel-tert-Butyl ((1R,2S)-2-fluorocyclopropyl)carbamate
IUPAC Nametert-butyl ((1R,2S)-2-fluorocyclopropyl)carbamate
Molecular FormulaC8H14FNO2
Molecular Weight175.20
SMILESO=C(OC(C)(C)C)N[C@H]1[C@@H](F)C1
InChI KeyVWSDKMQGCVVQBV-NTSWFWBYSA-N
SynonymCarbamic acid, (2-fluorocyclopropyl)-, 1,1-dimethylethyl ester, cis- (9CI);tert-butyl ((1R,2S)-2-fluorocyclopropyl)carbamate*;Sitafloxacin Impurity 25;rel-tert-Butyl ((1R,2S)-2-fluorocyclopropyl)carbamate
CAS No.105919-35-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACGRXL164 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACPGLZ157 route compound structure diagram
    ACPGLZ157141042-21-9In Stock
  4. Then
  5. ACGRXL164 route product structure diagram
    ACGRXL164105919-35-5
Inquiry

2. ACGRXL164 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGRXL164 route product structure diagram
    ACGRXL164105919-35-5
Inquiry

3. ACGRXL164 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGRXL164 route product structure diagram
    ACGRXL164105919-35-5
Inquiry

Comments (0)